We are pleased to announce that the Translational Cancer Research (TCR) has attained its latest impact factor update for the 2019 citation year: 0.986.
Translational Cancer Research (Transl Cancer Res, TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards.
Aiming for the continued development of article quality alongside the growth of the numbers of submissions, we have recently emphasized improving the publication quality and processing transparency. Some significant arrangements were made in TCR In the past few months:
1. Integration with Publons. As of April 2020, our publisher AME Publishing Company has entered into an official partnership with Publons. Thus, TCR’s peer review system is now integrated seamlessly into the Publons platform (https://publons.com/publisher/6041/ame-publishing-company). The partnership allows for the contributions of our expert peer-reviewers to be recognized anytime. For more information, see: http://tcr.amegroups.com/announcement/view/275.
2. Reporting guidelines for original research. For a higher standard of publishing and research quality, we have introduced a series of reporting guidelines for different research types. Each original research submission to TCR is now required to follow the EQUATOR research reporting guidelines and should include a checklist. If the article is accepted, the related reporting checklist will be published online with the article. For more details, please check the updated guidelines for authors: http://tcr.amegroups.com/pages/view/guidelines-for-authors.
3. Transparent peer review process. To commit to openness and accountability, and to increase the level of transparency throughout our peer review process, our Editorial Office has decided to implement a transparent peer review process as an option for all manuscripts submitted to TCR from March 19, 2020. Click here for further information: http://tcr.amegroups.com/announcement/view/265.
We strive to follow the best practices in publishing. The announcement of the journal’s latest impact factor is not only a significant achievement for the journal but also the recognition of its more significant scientific reach. Here, we would like to extend our heartfelt gratitude to all our Editorial Team Members, Guest Editors, authors, and reviewers for their significant contributions.
We look forward to the continuous cooperation with all the individuals mentioned above and those who are interested in translational cancer to bring more exciting content to readers in the coming future.
Translational Cancer Research
June 30, 2020